On November 9, 2021, Arbor Biotechnologies, Inc. closed the transaction. The transaction was led by new investors Temasek Holdings (Private) Limited, Ally Bridge Group, and TCG Crossover Management, LLC The transaction also included participation from other new investors Tekla Capital Management LLC, T. Rowe Price Group, Inc., Ridgeback Capital Management, LLC, Greatpoint Investment Management, LLC, Logos Capital Management, LLC, ArrowMark Colorado Holdings, LLC, Tao Capital Partners, IIF Management Company, LLC, Section 32, LLC, Janus Henderson Group plc, Woodline Partners LP, Piper Heartland Healthcare Capital, LLC, Deep Track Capital, LP, Ono Venture Investment, Citadel Multi-Strategy Equities Master Fund Ltd.; a fund managed by Citadel Advisors LLC, Vertex Pharmaceuticals Incorporated, and existing investors Arch Venture Partners, L.P., and an undisclosed global investment firm. The company raised $300,000,000 in funding till date.

Chen Yu of TCG Crossover Management will join the company's Board of Directors. The round was oversubscribed. The company has raised $214,999,926 through Regulation D in the transaction.

The transaction included participation from total 37 investors.